ISK received the FDA’s approval to start Phase 1b/2a with AML patients
January 9, 2020Related Posts
-
PHASE 1B/2A Clinical trial started
April 13, 2021 -
Cooperation with Harvard Medical School (MGH)
October 27, 2019ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases
-
Prof. Marc E. Lippman – Famous breast cancer expert (KOL ) has joined ISK Ltd
April 9, 2019Marc E. Lippman, MD, MACP FRCP is the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard School of Medicine, and was Chairman of the Department of Medicine from May 2007 to May 2012. He is currently Deputy Director of the Sylvester Comprehensive Cancer Center. Previously Dr. Lippman was the John […]
-
ISK attended the 2019 Sachs conference in Zurich
March 5, 2019 -
Prof. Rosenblatt, Joseph D, M.D, a KOL in hematology, has joined ISK’s advisory board
February 25, 2019
